Summit Therapeutics plc Summit Therapeutics Plc : Director/Pdmr Shareholding

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit" or the "Company") 
 
   Director / PDMR Share Dealing 
 
   Oxford, UK, Cambridge, MA, US, 17 July 2018 - Summit Therapeutics plc 
(AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 16 July 
2018 that Dr Frank Armstrong, Summit's Non-Executive Chairman, purchased 
25,000 ordinary shares of 1p each in the Company at 39.5 pence per 
share. 
 
   Following this purchase, his shareholding in the Company has increased 
to 39,442 ordinary shares, representing approximately 0.05% of the 
Company's issued share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
   Notification of a Transaction pursuant to Article 19(1) of Regulation 
(EU) No. 596/2014 
 
 
 
 
     Details of the person discharging managerial responsibilities/person 
1     closely associated 
a)   Name                                Frank Armstrong 
2    Reason for the notification 
a)   Position / status                   Non-Executive Chairman 
b)   Initial notification / Amendment    Initial notification 
     Details of the issuer, emission allowance market participant, 
3     auction platform, auctioneer or auction monitor 
a)   Name                                Summit Therapeutics plc 
b)   LEI                                 213800NRW8AOMYMTBD89 
     Details of the transaction(s): section to be repeated 
      for (i) each type of instrument; (ii) each type of 
      transaction; (iii) each date; and (iv) each place 
4     where transactions have been conducted 
     Description of the financial 
a)   instrument, type of instrument      Ordinary shares of 1 pence each 
 
     Identification code                 GB00BN40HZ01 
b)   Nature of the transactions          Purchase of ordinary shares 
c)   Price(s) and volume(s)               Price(s)                 Volume(s) 
   39.5 pence                                                             25,000 
 
d)   Aggregated information 
 - Aggregated volume 
 - Price 
e)   Date of the transaction             16 July 2018 
f)   Place of the transaction            London Stock Exchange 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients, and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for C. 
difficile infection and gonorrhoea and are using our proprietary Discuva 
Platform to expand our pipeline. For more information, visit 
www.summitplc.com and follow us on Twitter @summitplc. 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)             Tel:    [phone] 
Erik Ostrowski / Michelle Avery (US office)                   [phone] 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:   [phone] 
Liam Murray / Tony Rawlinson 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

July 17, 2018 02:00 ET (06:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.